Latest News

"Investment in research failing to keep pace with scope of Alzheimer’s" by Dr. David Morgan, CEO of USF Health Byrd Alzheimer’s Institute in Tampa, and lead representative of ResearchersAgainstAlzheimer’s.

Click here to read the letter to the editor from Dr. John Trojanowski, Director of the National Institute on Aging-funded Alzheimer's Disease Core Center in the Perelman School of Medicine at the University of Pennsylvania, and Founding Member of ResearchersAgainstAlzheimer's published on January 5, 2014 in the Scranton-Times Tribune. He argues that "the United States must take the lead in this concerted effort against Alzheimer's".

Dr. Rachelle Doody and Dr. John Trojanowski co-authored an op-ed regarding the Brain Initiative that was published November 19th in The Hill (the most widely circulated newspaper on Capitol Hill).

Please join us at the ResearchersAgainstAlzheimer's "Path to 2025 Reception" on Saturday, November 9th from 6 - 8pm at the Omni San Diego Hotel. Click here for a flyer and click here to RSVP. 

Here is an opportunity to weigh in on new Alzheimer’s research. You can help choose which of the three finalists will receive $50,000 from the Geoffrey Beene Global NeuroDiscovery Challenge to pursue groundbreaking research to understand sex-based differences in Alzheimer’s. 

Click here to read more about the three incredibly promising finalists and their research projects and cast your vote today. Please don’t delay, the winner will be announced live on November 7th at the CEOi Alzheimer’s Summit at the New York Academy of Sciences. 

Your vote can make a young researcher’s dream a reality, and help us...

Click here to view the comment from ResearchersAgainstAlzheimer’s, which was submitted to CMS on Friday, August 2. ResearchersAgainstAlzheimer’s requests that CMS reconsider and revise this proposed decision. Specifically, we request that CMS issue a National Coverage Determination for PET Aβ imaging for carefully defined patients with difficult-to-diagnose memory disorders, especially as described by the Appropriate Use Criteria (AUC) issued by the Amyloid Imaging Task Force (AIT).

Click here to read the letter urging the House Appropriations Committee to double the current level of funding for Alzheimer's research at NIH as part of an effort to ramp up to $2 billion within five years so that we can reach our national goal of preventing and effectively treating Alzheimer's disease by 2025.

Click here to read our letter urging the Senate Appropriations Committee to double the current level of funding for Alzheimer's research at NIH as part of an effort to ramp up to $2 billion within five years so that we can reach our national goal of preventing and effectively treating Alzheimer's by 2025.

Click here to read the comments submitted on Friday, May 10 on the "Interim Milestones to Complete the First Goal of the National Alzheimer's Plan by 2025" that were included in the recommendations by the Advisory Council on Alzheimer’s Research, Care and Service.

Click here to read the full letter.

ResearchersAgainstAlzheimer’s agrees with the importance of diagnosis and treatments at much earlier stages of Alzheimer’s disease. This draft guidance is based on the emerging understanding of Alzheimer’s research that treatments aimed at people showing overt functional impairments due to dementia won’t work because the damage to the brain may be too extensive at that point in the progression of the disease. Therefore, the appropriate response to this recently-­developed understanding is, as noted in the well-­considered draft guidance document of the FDA, to rely on a demonstration of a positive impact...

Pages